OBJECTIVE: To probe into the potential mechanism of Huazhi Rougan Granules in the treatment of non-alcoholic fatty liver disease（NAFLD） based on network pharmacology and molecular docking. METHODS: The drug compound targets were screened by using the Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform and the Encyclopedia of Chinese Medicine database

the disease targets of NAFLD were screened by using the GeneCards database and DigSee database

so that the related networks were constructed. Gene ontology function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes（KEGG） pathway enrichment analysis were performed for the shared targets by using R language. Finally

the molecular docking verification of key compounds and core targets was conducted

and the results were visualized by using Pymol software. RESULTS: The predicted core compounds were quercetin

kaempferol

luteolin and wogonin

the core targets were signal transduction and activating transcription factor 3

JUN

interleukin-6

tumor necrosis factor

CXCL8

vascular endothelial growth factor A

epidermal growth factor

interleukin-1β

chemokine ligand 2 and TP53. The results of KEGG pathway enrichment analysis showed that the pathways were associated with infectious diseases

immune system

endocrine and metabolic diseases

such as the AGE-RAGE signaling pathway

human cytomegalovirus infection and other signaling pathways in diabetic complications. CONCLUSIONS: The results of this study have initially validated and predicted the mechanism of Huazhi Rougan granules in the treatment of NAFLD

which laid a good foundation for further insight into its mechanism of action.